• Indian market opportunity: India accounts for one-third of the global dengue burden with prevalence increasing over 11-fold in the last two decades, presenting an eligible target population of more than 100 million individuals for Dr. Reddy's over the next three to five years.
• Commercial rollout strategy: Following a planned launch in the first half of 2027, Qdenga will initially debut in the private market before expanding into the national immunization program, with equitable pricing disclosed closer to the launch date.
• Clinical trial backing: Currently launched or approved in 43 countries with over 32 million doses distributed globally, the vaccine is supported by clinical trial data from approximately 80,000 subjects aged 4 to 60 years.
• Portfolio significance: Qdenga protects against all four circulating dengue serotypes found in India and is projected to become a top product across Dr. Reddy's entire pharmaceutical portfolio.